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Condensed Abstract: The prevalence and prognostic importance of CM occurring as a consequence of AF is poorly defined. This 
study investigated the incidence of CM in patients with AF, its clinical features and long-term outcomes. We demonstrated that CM is 
common in patients presenting acutely with newly diagnosed rapid AF, and carries a worse long-term prognosis. Systolic dysfunction 
was reversible in an important proportion of patients, suggesting a greater prevalence of rate-related CM in AF than has previously been 
postulated. This underscores the importance of appropriate rhythm management strategies and repeat imaging studies.
Summary
Background: Atrial fibrillation (AF) may precipitate LV dysfunction, potentially leading to cardiomyopathy (CM). The prevalence and 
prognostic importance of CM occurring as a consequence of AF is poorly defined. We investigated the incidence of CM in patients with 
AF, its clinical features and long-term outcomes.
Methods: We reviewed 292 consecutive patients (average age 72 ± 13yrs) presenting acutely with AF and tachycardia over a 3 year 
period from June 2004. Clinical details were obtained from medical records. CM was defined as ejection fraction (EF)  50% on index 
admission.
Results: Echo was performed 93% of patients at index admission, and 69 (24%) had CM (average EF% = 37 ± 11), 60 of which were 
newly diagnosed. Patients with CM had significantly higher presenting heart rate (141 ± 19 vs. 132 ± 23 bpm), larger end-diastolic 
(5.7 vs. 5.2 cm) and end-systolic (4.5 vs. 3.2 cm) dimensions, and larger left atrial size (4.6 vs. 4.3 cm) (p  0.05 for all). They were 
also statistically more likely (p  0.05) to be male, present with breathlessness, have a history of coronary disease, and be treated 
with digoxin and warfarin. Follow-up echo between 6 and 12 months was performed in 46% of patients with new CM, and average 
EF rose to 53 ± 12%. At an average follow-up of 2.5 years, there was a significant increase in mortality in CM patients (16% vs. 9.5%, 
p  0.05).
Conclusion: CM is common in patients presenting acutely with newly diagnosed rapid AF, and carries a worse long-term prognosis. Sys-
tolic dysfunction was reversible in an important proportion of patients, suggesting a greater prevalence of rate-related CM in AF than has 
previously been postulated. This underscores the importance of appropriate rhythm management strategies and repeat imaging studies.
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Introduction
Atrial  fibrillation  is  associated  with  significant 
  morbidity and mortality,1 and has been reported to be 
the most common cardiac arrhythmia.2 Its prevalence 
markedly  increases  with  age,  more  than  doubling 
for  every  successive  decade  of  life.1  Similarly  the 
  prevalence  of  congestive  heart  failure  (CHF)  is 
increasing and is also strongly associated with age.3 
AF and CHF are closely linked, but to what extent AF 
is a cause or consequence of ventricular systolic or dia-
stolic dysfunction is unclear.4 AF is a frequent compli-
cation of cardiomyopathy (CM) and heart failure, but 
animal studies and clinical reports have also indicated 
its potential to induce systolic dysfunction.5 AF results 
in loss of atrial contribution of ventricular filling, and 
inappropriately  rapid  and  irregular  ventricular  con-
tractions,  potentially  precipitating  left  ventricular 
dysfunction.6  Moreover,  it  has  been  demonstrated 
that CM in the setting of AF may be reversible, either 
with pharmacologic ventricular rate control,7 cardio-
version to sinus rhythm,8 or AV junction ablation and 
permanent ventricular pacing.9 However, the burden 
of CM occurring as a consequence of AF and its prog-
nostic importance is poorly defined.6 The purpose of 
this study was to investigate the incidence and clinical 
correlates of CM in patients presenting acutely with 
newly diagnosed AF, and to assess the importance of 
a rate-related aetiology in this setting.
Methods
We reviewed the clinical records of all patients pre-
senting with atrial fibrillation to the General Medical 
Service at North Shore Hospital, Waitemata Health, 
Auckland, New Zealand, for the period 2004–2007. 
Waitemata  Health  is  the  sole  provider  of  publicly 
funded medical services for a population of approxi-
mately 500,000 people, through two district general 
hospitals.  The  General  Medical  service  at  North 
Shore Hospital assesses an average of 16,000 acute 
referrals  for  inpatient  admission  annually.  Patients 
were included in this analysis if: (a) this was their 
first  documented  presentation  to  the  service  with 
atrial fibrillation and (b) if their ventricular response 
rate was recorded to be greater than 100 beats per 
minute on presentation. Those patients with a clinical 
presentation consistent with an acute coronary syn-
drome were excluded. The resulting analysis included 
292  consecutive  patients.  All  clinical  information 
  including  mortality  was  obtained  from  record  and 
database review, and patients underwent follow-up 
either at our institution or with their community pro-
vider after hospital discharge, as determined by the 
responsible clinician. In particular details of the index 
  admission  and  convalescent  echocardiograms,  if 
available, were documented. CM was defined as ejec-
tion fraction (EF) 50% on index echocardiogram. 
  Ejection  fraction  was  assessed  both  visually  and 
objectively using bi-plane Simpsons rule or the Tei-
chholz formula.
statistics
Analysis was undertaken using SPSS 17.0. Data are 
expressed as a mean ± standard deviation (SD). The 
baseline characteristics of the groups were compared 
using  students  t-test  for  continuous  variables,  and   
Chi-square  or  Fisher  Exact  tests  for  categorical 
  variables. Survival estimates and event rates were com-
pared by the Kaplan-Meier method. The log-rank test 
was used to compare the Kaplan-Meier survival curves. 
A p value of 0.05 was considered significant.
Results
The baseline clinical characteristics of the cohort are 
presented in Table 1. Of the 292 patients reviewed, 
69 (24%) were found to have an EF  50% on index 
echocardiogram, of which only 9 had a known pre-
existing CM. Normal LV systolic function was noted 
in 207, and only 13 (7%) patients did not have an 
echocardiogram performed in association with their 
index admission. They were excluded from the sub-
sequent analysis. Therefore overall 23% of patients 
with acute AF were found to have previously undi-
agnosed CM. Those patients found to have reduced 
systolic function had a significantly higher baseline 
heart rate (141 ± 19 vs. 132 ± 23 bpm, p  0.05), a 
greater likelihood of breathlessness being the primary 
presenting symptom (72% vs. 47%, p  0.05), and a 
trend towards an increased incidence of hypotension 
(10% vs. 5%, p = ns). A greater proportion of patients 
with CM received Digoxin (49% vs. 24%, p  0.05) 
and Warfarin (62% vs. 47%, p  0.05). Use of other 
antiarrhythmic  drugs  did  not  differ  significantly 
between the two groups, but it is notable that Class 1   
antiarrhythmic use was negligible.Cardiomyopathy in atrial fibrillation
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The echocardiographic data at index admission and 
subsequent follow-up is presented in Table 2. In the 
CM group the average index EF% was 37 ± 11%, as 
compared with 67 ± 8% in the patients without CM. 
The average end-diastolic dimension was increased 
in the CM group, but not significantly greater than in 
those without CM (5.7 vs. 5.2 cm, p = ns). However 
end-systolic dimension (4.5 vs. 3.2 cm) and left atrial 
size (4.6 vs. 4.3 cm) (p  0.05 for both) were signifi-
cantly greater in the CM group.
Follow-up  echocardiography  was  obtained 
between 6 and 12 months after index presentation in 
57 patients, 26 (43%) of whom had been found to have 
a newly diagnosed CM in association with AF. These 
patients had a significant increase in resting systolic 
function at repeat scanning, with the average EF rising 
to 53 ± 12%. This was associated with a normalisation 
in end-systolic dimensions (4.5 to 3.9 cm) and a small 
reduction in average left atrial size (4.6 to 4.4 cm). 
Figure 1 demonstrates graphically the outcome for 
all 26 patients of the initial 60 with newly diagnosed 
CM  who  underwent  follow-up  echocardiography, 
confirming that nearly all made significant gains in 
systolic function. Indeed 13 (50%) normalised their 
EF. At clinical follow-up, 11 (42%) of those patients 
Table 1. Baseline characteristics of the study cohort.
  cM nO cM
number of patients 69 207
Patient Characteristics (n,%):
  Age (years) (Mean ± sD) 72 ± 11 72 ± 13
  sex (Male%) 67% 48%
  Known Cardiomyopathy 9 (13%) 7 (3%)*
  Ischaemic heart Disease 28 (41%) 60 (29%)
  hypertension 30 (43%) 90 (44%)
  Valvular heart Disease 7 (10%) 25 (12%)
Primary symptom on admission (Mean ± sD)
  Palpitations 23 (33%) 127 (61%)*
  Breathlessness 50 (72%) 97 (47%)*
  Chest pain 19 (28%) 80 (39%)
Clinical findings on admission
  resting heart rate (Mean ± sD) 141 ± 19 132 ± 23*
  hypotension (BP  100 mmhg systolic) 7 (10%) 11 (5%)
Medication at discharge (n,%):
  Beta-blockers 44 (64%) 123 (59%)
  Calcium channel blockers 37 (54%) 96 (46%)
  Digoxin 34 (49%) 49 (24%)*
  Amiodarone 15 (22%) 48 (23%)
  Class I antiarrhythmic 1 (1%) 13 (6%)
  Aspirin 47 (68%) 132 (64%)
  Warfarin 43 (62%) 98 (47%)*
Values are means ± sD, or numbers of patients (percentages).
*p  0.05.
Table 2. echocardiography results.
  cM nO cM
echocardiography data  
on admission (Mean ± sD)
  LVeDD (cm) 5.7 ± 0.9 5.2 ± 3.3*
  LVesD (cm) 4.5 ± 0.9 3.2 ± 1.7*
  ejection Fraction (%) 37 ± 11 67 ± 8*
  LA size (cm) 4.6 ± 0.9 4.3 ± 0.8*
echocardiography data  
at 6 months (Mean ± sD)
  LVeDD (cm) 5.7 ± 0.7 5.0 ± 1.0
  LVesD (cm) 3.9 ± 0.8 3.4 ± 0.9
  ejection Fraction (%) 53 ± 12 62 ± 13
  LA size (cm) 4.4 ± 0.8 4.5 ± 0.6
Values are means ± sD, or numbers of patients (percentages).
*p  0.05.Lin et al
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with  newly  diagnosed  CM  undergoing  follow-up 
echocardiogram were in sinus rhythm, 1 was paced, 
and the average heart rate of those who remained 
in AF was 82 ± 17 bpm, suggesting acceptable rate 
control in the majority.
In  the  entire  cohort  there  were  30  deaths  over 
an  average  follow-up  period  of  2.5  years.  Deaths 
were significantly higher in the CM group (16% vs. 
9.5%) and this is illustrated in Figure 2, showing the 
significantly worse mortality in those patients with 
newly diagnosed CM in the setting of acute AF and 
tachycardia.
Discussion
This  study  identifies  that  previously  unsuspected 
CM  is  common  in  patients  presenting  acutely 
with  newly  diagnosed  rapid AF,  and  that  patients 
with  CM  in  this  setting  have  a  worse  long-term 
prognosis. Furthermore we have demonstrated that 
in an important proportion of patients this systolic 
dysfunction is reversible. This suggests a potentially 
greater prevalence of rate-related CM in AF than has 
previously been postulated.
Reversible LV dysfunction associated with rapid 
AF has been recognised for decades, and was first 
discussed in detail by Phillips and Levine in 1949.10 
However the evidence confirming this relationship 
and  defining  the  causal  link  is  surprisingly  scant. 
Grogan et al7 reported a small series of 10 patients 
initially  considered  to  have  idiopathic  dilated  CM 
who  had  a  gain  in  median  ejection  fraction  from 
25% to 52% after adequate rate control or restora-
tion of sinus rhythm. Similarly Kieny et al8 reported 
12 patients with chronic AF and average EF of 32% 
who were successfully restored to sinus rhythm. This 
was associated with a 20.8% average improvement 
in EF, and 6 (50%) of the patients returned to nor-
mal  systolic  function.  More  recently  improvement 
Figure 1. graphical representation of the index and follow-up eF for all 26 patients of the initial 60 with newly diagnosed CM who underwent follow-up 
echocardiography, confirming that nearly all made significant gains in systolic function. Note that 13 (50%) normalised their EF.
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in cardiac function of a similar magnitude has been 
seen in patients with CM and AF refractory to therapy 
who were treated either with AV node ablation and 
pacemaker implantation,9 or who underwent catheter 
  ablation.11 From this later work, Cha et al postulated 
that the prevalence of AF-induced CM was 10% in 
this challenging group.4
Our study reviewed a considerably larger cohort 
of  patients  with AF  than  those  studies  cited  thus 
far, and focussed on those presenting acutely to an 
emergency  department  with  tachycardia.  Overall 
23% of patients with acute AF were found to have 
previously  undiagnosed  CM.  However  the  causes 
of CM in our group are likely heterogeneous, and 
include (but are not limited to) idiopathic dilated 
CM, myocarditis and rate-related CM. In particular 
in this study the duration of AF prior to presentation 
to  the  emergency  department  is  unclear.  The 
development  of  a  tachycardia-related  myopathy 
requires an element of chronicity to the dysrhythmia, 
further suggesting that not all cases of impaired LV 
function in our series are related solely to rapid AF. 
However the finding that 50% of those patients with 
newly diagnosed CM in the setting of AF returned 
to normal systolic function at follow-up replicates 
Kieny’s results, and supports the hypothesis that this 
group indeed had AF-induced CM. The CM group in 
our series also had a higher average presenting heart 
rate, but no information can be gleaned on whether 
this was a cause for, or a consequence of, the systolic 
dysfunction. It should be noted however that patients 
seen  at  follow-up  were  almost  uniformly  in  well 
rate-controlled AF or sinus rhythm. Furthermore it 
is interesting to note that the average end diastolic 
dimension in our patients with CM was only margin-
ally about the upper limit of normal, supporting the 
concept of an acute rate-related dysfunction without 
marked LV dilation.
Figure 2. Kaplan-Meier analysis showing the significantly worse mortality (p  0.05) in those patients with newly diagnosed CM in the setting of acute AF 
and tachycardia, as compared with patient with no CM.
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There is a limited understanding of the mecha-
nisms  underlying  tachycardia-induced  myopathy. 
The majority of our understanding is derived from 
animal  studies  of  pacing-mediated  CM.  Morrison 
et  al6  summarise  the  evidence  and  hypotheses  in 
three categories: structural changes, cellular changes 
and increased sympathetic nerve activity. Changes 
in extracellular collagen distribution and increased 
  myocardial  stiffness  are  noted,  along  with  deple-
tion  of  myocyte  energy  stores  and  abnormal  cal-
cium metabolism. Unfortunately our study does not 
provide any further insights into the mechanisms of 
myopathy.
Framingham  study  data  have  demonstrated  that 
AF is an independent predictor of mortality in men 
and women of all ages.1 Furthermore the subsequent 
development of CHF in patients with known AF was 
associated  with  increased  mortality  for  both  men   
(HR 2.7; 95% CI, 1.9 to 3.7), and women (HR 3.1; 
95% CI, 2.2 to 4.2).12 Similarly our study suggested 
that, at an average follow-up of 2.5 years, there was an 
increase in mortality for those patients with acute AF 
and newly diagnosed CM patients (16% vs. 9.5%). 
Patients whose LV function improved (LVEF  45%) 
after atrioventricular node ablation have been shown 
to have a comparable survival to age-and sex-matched 
controls, and better than that noted in patients with 
persistent LV dysfunction.9 None of the patients in 
our study who normalised their LV function died dur-
ing follow-up, but the numbers available for analysis 
were very limited.
Limitations
This is a retrospective clinical review and suffers the 
major limitations associated with this type of study. 
Most notable in our series is the lack of consistent 
clinical  follow-up  and  echocardiography,  even  in 
patients  with  confirmed  systolic  dysfunction  on 
index admission. This reduces the reliability of the 
data regarding recovery of LV function, but does 
not  impact  the  information  gained  on  prevalence 
or  prognostic  importance  of  CM  in  this  setting. 
A  further  potential  limitation  is  the  challenge  in 
assessing  LV  systolic  function  in  the  setting  of 
tachycardia, especially fast AF. Echocardiographic 
may result in spuriously low estimations of EF%. 
We are unable to further clarify this issue, but would 
note that echocardiograms were performed in the 
days following admission to an inpatient service—at 
a time when rate control was likely to have improved 
over that on presentation to the emergency depart-
ment. Although  a  very  small  number  of  patients 
underwent cardiac magnetic resonance imaging in 
convalescence, there was no rigorous assessment to 
exclude or confirm myocarditis. It is therefore not 
possible to resolve the true proportion of CM that 
was induced by AF alone. Similarly it is not feasible 
to account for the potential effect of optimal phar-
macologic therapy for systolic dysfunction on the 
subsequent improvement in EF seen in the follow-
up echocardiograms.
Conclusions
We  have  demonstrated  that  CM  is  common  in 
patients  presenting  acutely  with  newly  diagnosed 
rapid AF, and carries a worse long-term prognosis. 
Systolic  dysfunction  is  reversible  in  an  important 
proportion  of  patients,  suggesting  a  greater  preva-
lence of rate-related CM in AF than has previously 
been postulated. This underscores the importance of 
appropriate rhythm management strategies and repeat 
imaging studies.
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